

Market Applicability/Effective Date														
Market	FL & FHK*	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Medication	Quantity Limit
Incivek (telaprevir)	six tablets per day

OVERRIDE(S)

Prior authorization of benefits

APPROVAL DURATION

12 weeks (no interim assessment required)

APPROVAL CRITERIA

Requests for Incivek (telaprevir) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Documentation is provided for a diagnosis of Hepatitis C Genotype 1; **AND**
- III. Using in combination with peginterferon alfa and ribavirin; **AND**
- IV. Individual has compensated liver disease^a

Child-Pugh Score, also known as Child-Turcotte-Pugh (CTP) score: a scoring system for severity of liver disease and likelihood of survival based on the presence of: degenerative disease of the brain (encephalopathy), the escape or accumulation of fluid in the abdominal cavity (ascites), laboratory measures of various substances in the blood (see table below), and the presence of other co-existing diseases. After calculating the CTP score using a table similar to the one below, classify individuals into one of three categories:

- Childs A (5-6 points): 10 year survival 80-90%
- Childs B (7-9 points): five year survival 60-80%
- Childs C (10-15 points): two year survival less than 50%

Child-Pugh Classification

Variable	One Point	Two Points	Three Points
Encephalopathy	None	Moderate	Severe
Ascites	None	Mild	Moderate
Albumin (mg/dL)	> 3.5	2.8-3.5	< 2.8
Prothombin time (International Normalized ratio) prolonged	Less than 4	4-6	Greater than 6
Bilirubin (mg/dL) Primary biliary cirrhosis	1-4	4-10	Greater than 10

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

PEC-ALL-1267-14-Incivek

Cirrhosis/primary Primary sclerosing cholangitis			
All other diseases	Less than 2	1-3	Greater than 3

^aCompensated liver disease: Child-Pugh score less than or equal to 6 (Childs A) in cirrhotic individuals before or during treatment

Decompensated liver disease: Child-Pugh score greater than 6 (Childs B or C) in cirrhotic individuals before or during treatment

Note: Incivek (telaprevir) has a black box warning for fatal and non-fatal skin reactions (such as Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms and toxic epidermal necrolysis). Fatalities have resulted when individuals with progressive rash and systemic symptoms continued Incivek combination treatment after the rash was identified. If rash with systemic symptoms or progressive severe rash occurs, Incivek combination therapy (Incivek, peginterferon alfa and ribavirin) must be discontinued immediately. Discontinuation of any other medications that may cause serious skin reactions should be considered. Refer individuals for urgent medical care.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.